Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Unimed Pharmaceutical
Seoul, Songpa-gu, South Koreauniversalmarinemedical.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Unimed Pharmaceutical has a commercial-stage pipeline with at least one approved product and several others in various stages of development or discontinued. Notable drugs include alprazolam for anxiety disorders and spirogermanium hydrochloride for rheumatic diseases. The company also previously developed oxymetholone for cachexia and dronabinol for pain.
- Therapeutic areas
- PsychiatryRheumatologyOncologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Unimed Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unimed Pharmaceutical.